Hepatitis C, Chronic: all 1,090 studies
Page 7 of 11. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.
- A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus InfectionCompletedNCT02593162Phase 2
- Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in IndiaCompletedNCT02592057
- Switching Regimen in Treating Cirrhotic HCV GT1b SubjectsCompletedNCT02583685Phase 2
- Project BEST: Buprenorphine Entry Into Substance Abuse TreatmentCompletedNCT02583243
- Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)CompletedNCT02578693
- Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected PatientsCompletedNCT02576314Phase 3
- A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)WithdrawnNCT02556086Phase 2
- DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)CompletedNCT02555943Phase 2/3
- Hepatitis C Virus in Neutrophil Granulocyte Progenitor CellsWithdrawnNCT02545387
- Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis CCompletedNCT02545335
- Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization PeriodCompletedNCT02531269
- Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis CCompletedNCT02528461
- Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis CCompletedNCT02526641
- A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy VolunteersCompletedNCT02512562Phase 1
- Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in AndalusiaStatus unknownNCT02511496
- A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection TrialsTerminatedNCT02510300
- First in Human Study of AL-704; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis CTerminatedNCT02510248Phase 1
- Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus RibavirinCompletedNCT02508090
- Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA RegimensCompletedNCT02505243
- A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus InfectionCompletedNCT02498015Phase 4
- A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b InfectionCompletedNCT02496078Phase 3
- Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1WithdrawnNCT02485080Phase 4
- Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected PatientsCompletedNCT02482077Phase 4
- Neutrino Regimen for Treatment-experienced HCV GT1 PatientsCompletedNCT02480686Phase 4
- SOF Plus DCV in Treating Chinese Treatment-experienced HCV PatientsCompletedNCT02473211Phase 2/3
- Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b SubjectsCompletedNCT02470858Phase 2
- Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral TherapyStatus unknownNCT02469012Not applicable
- Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 InfectionCompletedNCT02452814
- Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century KinshasaCompletedNCT02439918
- Transient Elastography to Assess Liver Fibrosis and Portal Hypertension in HCV Cirrhotic Patients Treated With New Antiviral Drugs (SPLEEN-C)CompletedNCT02439567Not applicable
- Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver FibrosisCompletedNCT02400216
- An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.WithdrawnNCT02397395Phase 2
- A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4Status unknownNCT02371408Phase 2/3
- First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1CompletedNCT02339207Phase 1
- A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug UseCompletedNCT02336139Phase 2
- Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life ConditionsCompletedNCT02333292
- Primary Prevention Hepatocellular Carcinoma by MetforminTerminatedNCT02319200Phase 3
- Phase I-II Vaccination of Autologous Dendritic Cells Transduced With Adenoviral Vector Encoding NS3 in Hepatitis C Encoding NS3 in Hepatitis CTerminatedNCT02309086Phase 1/2
- Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based TherapiesTerminatedNCT02293941Phase 2
- Impact of HCV Treatment on Neurocognitive Functions and Brain MetabolismWithdrawnNCT02292966Phase 4
- Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV PatientsCompletedNCT02282709Phase 3
- Evaluation of the Antiviral Pharmacodynamic Effect, Safety, and Pharmacokinetics of Escalating Doses of BILB 1941 ZW to Patients With Chronic Hepatitis C Genotype 1 Virus InfectionCompletedNCT02254707Phase 1/2
- Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus InfectionCompletedNCT02253550Phase 2
- Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis CCompletedNCT02250001
- Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Chronic Hepatitis C Virus InfectionCompletedNCT02226952Phase 1/2
- Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis CCompletedNCT02226939Phase 2
- Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot StudyCompletedNCT02220868Phase 4
- Effect of Camel Milk on Chronic Hepatitis CCompletedNCT02216045Phase 2
- A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis CWithdrawnNCT02206932Phase 4
- Hepatitis C Alcohol Reduction TreatmentCompletedNCT02176980Not applicable
- Pirfenidone, an Antifibrotic and Antiinflammatory DrugCompletedNCT02161952Phase 2
- A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis CNo longer availableNCT02161939
- Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) InfectionStatus unknownNCT02126137Phase 1
- UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis CCompletedNCT02123654Phase 3
- Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis CCompletedNCT02123212Not applicable
- Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis CTerminatedNCT02120274Phase 4
- Comparative Effectiveness and Tolerability of Boceprevir vs TelaprevirCompletedNCT02113631Not applicable
- Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected SubjectsTerminatedNCT02112942Phase 1
- Hepatitis C in Renal Transplant RecipientsStatus unknownNCT02108301Phase 4
- Evaluation of the National Treatment Program of Hepatitis C in EgyptWithdrawnNCT02101177
- Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis CWithdrawnNCT02099604Phase 3
- EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis CNo longer availableNCT02097966
- Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for TestingCompletedNCT02068963
- Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C PatientsCompletedNCT02065999
- The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C PatientsCompletedNCT02063607Phase 1
- Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)Status unknownNCT02057887Phase 1/2
- Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected PatientsStatus unknownNCT02057003
- Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD)Status unknownNCT02038387Not applicable
- Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCVCompletedNCT02027493Not applicable
- Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C InfectionCompletedNCT02027116Phase 1
- Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.CompletedNCT02014571Phase 1
- Prospective Observational Study of Disease Progression in Chronic Hepatitis CActive, not recruitingNCT02011932
- Patient Self-management and Gene Guided Therapy for Chronic Hepatitis CCompletedNCT02006823
- Long Term Vitamin D Therapy in HCV Treated PatientsTerminatedNCT01997203Phase 3
- Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis CCompletedNCT01980290
- UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic SubjectsCompletedNCT01979939Phase 3
- UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated CirrhosisCompletedNCT01973049Phase 3
- Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve PatientsCompletedNCT01970904Not applicable
- Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In CirrhosisTerminatedNCT01951209Not applicable
- A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCVStatus unknownNCT01949168Phase 2
- Observational Study in HCV Chronic InfectionCompletedNCT01945008
- A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C PatientsCompletedNCT01928147Phase 1
- Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)CompletedNCT01919125Phase 1
- Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life ConditionsCompletedNCT01908660
- A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis CCompletedNCT01908335Phase 2
- Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)CompletedNCT01907724Phase 1
- A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis CCompletedNCT01903954Phase 2
- Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis CCompletedNCT01903278Phase 3
- Epidemiological Study to Evaluate Personality Disorders in Prison Populations in Treatment for Hepatitis CStatus unknownNCT01900886
- Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis CCompletedNCT01899092Phase 1/2
- Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian PopulationStatus unknownNCT01896609Phase 4
- The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)WithdrawnNCT01890200Phase 3
- Comparative Pharmacokinetics and Pharmacodynamics of Peginterferon BIP48 and 40kDa in Healthy VolunteersCompletedNCT01889849Phase 1
- An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis CCompletedNCT01889433Phase 3
- Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4CompletedNCT01884402
- A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy SubjectsCompletedNCT01879462Phase 1
- Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus InfectionStatus unknownNCT01872936Phase 2
- Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis CWithdrawnNCT01871662Phase 2/3
- Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis CCompletedNCT01859962Phase 2
- Open Label Trial to Compare BI 207127 to Telaprevir in HCV PatientsWithdrawnNCT01858961Phase 3